AccuRXy

Elevator pitch

AccuRXy in three slides

An overview. The full deck holds the detail.

The problem and the product01 / 3

Medication harm is costly and preventable, yet training and governance remain manual

$42bn

Lost every year to medication errors, against a WHO goal to halve severe avoidable harm.

What is still done by hand

  • Universities write and check learning cases one at a time, never fast enough for what students need
  • In pharmacies, incident reports, follow-up actions, procedures and training records sit in paper and spreadsheets
  • So an owner or chief pharmacist has no single view of risk before an inspection

What AccuRXy is

  • Educate, for universities: realistic scenario practice at the volume students ask for, approved by their own faculty
  • Regulate, for pharmacies: report, investigate and correct medication incidents in one workflow, inspection-ready
  • One engine behind both, so every scenario records the guidance it came from and who approved it

Where we are: building and in trial preparation, with four trials committed across universities and Irish pharmacy.

Who pays, and how much02 / 3

Two products, two distinct buyers, priced per seat and per site

€89

Educate: per student per year

Universities and colleges

€3,000

Regulate: per pharmacy site per year

Owners and superintendents

Illustrative annual recurring revenue

  • €107k to €178k a year from 3 to 5 schools on Educate
  • €150k a year from 50 pharmacy sites on Regulate

Why both, not one

  • The academic sale builds credibility and the evidence base
  • The pharmacy sale pays more per customer and is closer to revenue
  • Neither needs a second product to be built

These are modelled scenarios and price points under test, not forecasts or commitments.

The ask03 / 3

Seeking €900k at Seed to convert four trials into first paid contracts

€900k

Seed round

Target close June to August 2027

4 trials

Academic and Regulate

Running to September 2027

Aug 2027

Intent to pay

3 to 5 institutions

Use of funds

Product and trials50% · €450k
Go-to-market30% · €270k
IP, legal and contingency20% · €180k

What the round proves

  • Documented evidence that educators save time and students improve
  • A Regulate buying decision with an Irish pharmacy operator
  • Measured production cost per scenario and a costed business model
  • Three to five institutions ready to pay